Phase 2 N=159 Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Glioblastoma
Primary: Overall Survival Rate at 12 Months (OS-12) as Estimated Using the Kaplan-Meier Method (Cohort A) — 60.0 percent of subjects alive
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=213 Study of the Efficacy and Safety of MEDI4893
Staphylococcus Aureus Pneumonia
Primary: Percentage of Participants With Endpoint Adjudication Committee-Determined (EAC) Staphylococcus Aureus (S Aureus) Pneumonia — 26.0; 20.0; 17.7 Percentage of Participants…
Phase 2 N=130 Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
Breast Cancer · Estrogen Receptor-Positive Breast Cancer · Breast Cancer, Estrogen Receptor-Positive
Primary: Progression-free Survival (PFS) — 2.27; 4.28 months — p=0.06
Phase 2 N=146 Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel
Pancreatic Cancer
Primary: Deterioration-free Survival Rate of the QOL Global Health Status at 3, 6 and 12 Months (Mos) — 89; 73; 74; 59 percentage of participants
Phase 2 N=12 EEG Studies of Sevoflurane-Induced General Anesthesia
Anesthesia
Primary: Frequencies At Which Changes in Alpha, Theta, and Slow-Delta Wave Power Were Observed From Baseline During Sevoflurane-induced General Anesthesia — 10; 5; 1 Hz
Phase 2 N=126 Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12 — 35.8; 43.5; 11.8 percentage of participants — p=0.002
Phase 2 N=47 Human Laboratory Study of Varenicline for Alcohol Use Disorder
Alcohol Use Disorder
Primary: Cue-elicited Craving — 2.1; 2.2 units on a scale
Phase 2 N=339 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Objective Response Rate — 15.5; 14.6; 19.3; 18.8 percentage of participants
Phase 2 N=11 Oxytocin and Stress Response in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Corticolimbic Functional Connectivity Based on fMRI Blood Oxygenation Level Dependent (BOLD) Response During the Stress Versus Neutral Conditions of the Montreal Imaging…
Phase 2 N=1,051 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)
Pneumococcal Infections
Primary: Percentage of Participants Achieving the Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Threshold Value of ≥0.35 µg/mL for the 13 Common Serotypes in…
Phase 2 N=789 Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
Irritable Bowel Syndrome
Primary: Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 4…
Phase 2 N=260 Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis
Osteoarthritis of the Knee
Primary: Pain When Walking On A Flat Surface — 0; 1; 8; 4 Participants
Phase 2 N=24 Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Lymphoma · Mantle Cell Lymphoma · Indolent Lymphoma
Primary: Progression-free Survival at 2 Years — 15 Participants
Phase 2 N=185 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
Refractory Chronic Cough
Primary: Change in 24-hour Objective Cough Frequency (Log Normalized Percent Change Relative to Placebo) — -0.18; -0.45 coughs/hr — p=0.9942
Phase 2 N=23 Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Melanoma
Primary: Ganglioside Expressed by Tumor Cells (GD2) — 3; 3; 3; 3 Participants